MaltSci 麦伴科研

Appearance

Popular Reports / Immunology

This report is written by MaltSci based on the latest literature and research findings

How does the immune system respond to vaccines? ​

Abstract ​

Vaccination is one of the most effective public health interventions, significantly reducing the incidence of infectious diseases worldwide. Understanding the immune system's response to vaccines is essential for optimizing vaccine design and improving efficacy and safety. The immune response to vaccination involves complex interactions between innate and adaptive immune cells, leading to immediate and long-term protective immunity. Upon vaccination, the innate immune system is the first to respond, activating immune cells such as dendritic cells and macrophages, which process antigens and present them to T cells. This initiates the adaptive immune response, characterized by the activation of T and B lymphocytes. The formation of immunological memory is critical for long-term protection, allowing the immune system to respond swiftly upon re-exposure to pathogens. Various factors, including age, genetic predispositions, and pre-existing immunity, influence individual vaccine responses, highlighting the need for personalized vaccination strategies. Innovations in vaccine development, including novel platforms and adjuvants, are paving the way for enhanced immune responses and improved public health outcomes. This review synthesizes current knowledge on the immune response to vaccines, providing insights that can inform future vaccine strategies.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 The Immune System: An Overview
    • 2.1 Components of the Immune System
    • 2.2 Innate vs. Adaptive Immunity
  • 3 Mechanisms of Vaccine-Induced Immunity
    • 3.1 Antigen Presentation and Recognition
    • 3.2 Activation of T and B Cells
  • 4 Immunological Memory and Long-Term Protection
    • 4.1 Formation of Memory Cells
    • 4.2 Role of Memory in Vaccine Efficacy
  • 5 Factors Influencing Vaccine Response
    • 5.1 Age and Immune Status
    • 5.2 Genetic Factors and Pre-existing Immunity
  • 6 Innovations in Vaccine Development
    • 6.1 Novel Vaccine Platforms
    • 6.2 Role of Adjuvants and Delivery Systems
  • 7 Conclusion

1 Introduction ​

Vaccination has been recognized as one of the most effective public health interventions in history, dramatically reducing the incidence of infectious diseases across the globe. The mechanisms by which vaccines stimulate the immune system, however, remain a complex and multifaceted area of study. Understanding how the immune system responds to vaccines is crucial not only for optimizing vaccine design but also for improving efficacy and safety profiles. The immune response to vaccination involves intricate interactions between various immune cells and signaling molecules, which are pivotal in establishing both immediate and long-term protective immunity. Recent advances in immunology and technology have allowed researchers to explore these responses more comprehensively, paving the way for innovations in vaccine development and deployment [1][2].

The significance of this research is underscored by the ongoing global health challenges posed by infectious diseases, as exemplified by the COVID-19 pandemic. Vaccines play a vital role in achieving herd immunity and mitigating disease spread, yet the variability in individual immune responses to vaccination necessitates a deeper understanding of the underlying mechanisms [3][4]. As vaccine strategies evolve, so too must our comprehension of the immune system's complexities, particularly the balance between innate and adaptive immunity, the formation of immunological memory, and the impact of various factors such as age, genetics, and pre-existing immunity [5][6].

Current research has begun to elucidate the dual nature of immune responses elicited by vaccines, highlighting the roles of both the innate and adaptive immune systems. The innate immune response serves as the first line of defense, rapidly activating and coordinating subsequent adaptive responses characterized by the activation of T and B lymphocytes [7][8]. Understanding the dynamics of these responses is essential for improving vaccine efficacy and developing new vaccine platforms that can cater to diverse populations [9][10].

This review is organized into several key sections that will address the following topics: First, we will provide an overview of the immune system, detailing its components and the distinctions between innate and adaptive immunity. Next, we will delve into the mechanisms of vaccine-induced immunity, focusing on antigen presentation, recognition, and the activation of T and B cells. Following this, we will explore the formation of immunological memory and its role in providing long-term protection against pathogens. Additionally, we will discuss various factors influencing vaccine responses, including age, immune status, and genetic predispositions. Finally, we will examine innovations in vaccine development, including novel platforms and the role of adjuvants and delivery systems, before concluding with insights into future directions for vaccine research and public health implications.

By synthesizing current knowledge in this field, this review aims to provide a comprehensive understanding of how the immune system responds to vaccines, thereby informing future vaccine strategies and enhancing global health outcomes.

2 The Immune System: An Overview ​

2.1 Components of the Immune System ​

The immune system is a complex network of specialized cell types and tissues that work in concert to orchestrate specific defensive responses against pathogens. When a vaccine is administered, it activates this intricate system, leading to a series of immunological events that involve both innate and adaptive immunity.

Upon vaccination, the innate immune system is typically the first to respond. This response includes the activation of various immune cells such as dendritic cells, macrophages, and natural killer cells, which recognize the vaccine's antigens through pattern recognition receptors. These cells play a crucial role in processing the antigens and presenting them to T cells, thereby initiating the adaptive immune response. The innate immune response is characterized by the production of cytokines and chemokines, which help to recruit and activate additional immune cells at the site of vaccination [4].

The adaptive immune response is more specific and involves the activation of T and B lymphocytes. Following antigen presentation, helper T cells (CD4+ T cells) and cytotoxic T cells (CD8+ T cells) are activated. Helper T cells facilitate the activation of B cells, which are responsible for producing antibodies specific to the vaccine's antigens. This process leads to the generation of memory B cells and long-lived plasma cells that secrete antibodies, providing long-term immunity [7].

Recent advancements in systems immunology have allowed for a more comprehensive understanding of vaccine responses. By measuring multiple responding cells and cytokines in the blood, researchers can obtain a holistic view of the immune system's mobilization during vaccination. This approach has enabled the identification of early innate signatures that predict the immunogenicity of vaccines, revealing how different components of the immune system interact [1].

Studies have shown that the immune response to vaccination can vary significantly among individuals, influenced by factors such as age, sex, genetic predispositions, and prior exposure to pathogens. For instance, older adults often exhibit suboptimal responses to vaccines due to immunosenescence, a decline in immune function associated with aging [11]. Moreover, the composition of the intestinal microbiome has also been implicated in modulating vaccine responses, suggesting that a balanced microbiome may enhance immunogenicity [8].

In summary, the immune response to vaccines is a multi-faceted process that involves the coordinated action of innate and adaptive immune components. Vaccination not only induces specific antibody production but also primes the immune system for future encounters with pathogens, thereby establishing a robust memory response that is crucial for long-term protection [5].

2.2 Innate vs. Adaptive Immunity ​

The immune response to vaccines is a complex interplay between the innate and adaptive immune systems, which can be characterized by a series of biological processes that occur following vaccination. Vaccines are designed to stimulate the immune system to recognize and combat pathogens without causing the disease itself.

Upon vaccination, the innate immune system is the first line of defense. It responds rapidly to the vaccine by recognizing the components of the vaccine (such as antigens) through pattern recognition receptors (PRRs). This initial response leads to the activation of various immune cells, including macrophages, dendritic cells, and natural killer (NK) cells, which release cytokines and chemokines that facilitate inflammation and recruit additional immune cells to the site of vaccination. For instance, studies have shown that the first dose of a vaccine can lead to increased levels of innate cytokines, indicating a robust initial immune response[3].

Following this innate response, the adaptive immune system is activated. This system is characterized by a slower but more specific response, involving the activation of T and B lymphocytes. T cells can be divided into helper T cells (Th cells) and cytotoxic T cells, which play crucial roles in orchestrating the immune response and directly killing infected cells, respectively. B cells, on the other hand, are responsible for producing antibodies that specifically target the antigens introduced by the vaccine. The activation of these cells leads to the formation of memory cells, which provide long-term immunity by "remembering" the specific pathogens encountered[4].

The type of vaccine administered can significantly influence the nature of the immune response. For example, mRNA vaccines and viral vector vaccines tend to promote a Th1 response, which is associated with a strong cellular immune response, while inactivated vaccines, such as CoronaVac, may skew the response towards a Th2 profile, characterized by increased antibody production and a focus on humoral immunity[3]. This differential response underscores the importance of vaccine design in shaping the desired immune outcomes.

Furthermore, systems biology approaches have been employed to analyze the immune responses to vaccination, revealing that different vaccines induce distinct transcriptional signatures associated with immune activation[12]. For example, a study found that the immune response to influenza vaccination showed marked upregulation of genes involved in interferon signaling and antigen processing within the first 24 hours post-vaccination, which correlates with the magnitude of the antibody response[13].

In conclusion, the immune response to vaccines is a well-coordinated process involving both innate and adaptive immunity. The initial response is dominated by innate immune mechanisms, which lay the groundwork for the subsequent adaptive immune response, leading to the production of antibodies and the formation of immunological memory. Understanding these processes is critical for optimizing vaccine efficacy and developing new vaccination strategies.

3 Mechanisms of Vaccine-Induced Immunity ​

3.1 Antigen Presentation and Recognition ​

The immune response to vaccines is a complex interplay between various components of the immune system, primarily involving antigen presentation and recognition. Vaccines work by eliciting an immune response that leads to the generation of immunological memory, which provides protection against future infections or diseases. Understanding the mechanisms underlying this response is crucial for improving vaccine efficacy.

Vaccines typically introduce antigens—substances that provoke an immune response—into the body. These antigens can be derived from inactivated or attenuated pathogens, or they may be subunit vaccines that contain purified components of pathogens. The immune system recognizes these antigens through specialized cells known as antigen-presenting cells (APCs), which include dendritic cells, macrophages, and B cells. These cells process the antigens and present them on their surface using major histocompatibility complex (MHC) molecules.

There are two primary pathways for antigen presentation: MHC class I and MHC class II. MHC class I molecules present endogenous antigens, typically derived from intracellular proteins, to CD8+ cytotoxic T cells, while MHC class II molecules present exogenous antigens, typically from extracellular sources, to CD4+ helper T cells. For a robust immune response, both CD4+ and CD8+ T cell activation is essential. The processing and presentation of antigens to these T cells can be enhanced by various factors, including the use of molecular adjuvants, which can improve the immunogenicity of the vaccine (Beláková et al., 2007; Coban et al., 2013).

The immune system's recognition of lipid antigens also plays a significant role in the response to certain vaccines. Recent studies indicate that lipid-specific T cell responses occur more frequently than previously thought, and understanding the mechanisms of lipid presentation can facilitate the development of lipid-based vaccines (De Libero & Mori, 2005).

Moreover, advancements in systems biology have allowed for a more comprehensive understanding of the immune response to vaccines. This approach has revealed that the innate immune system is crucial in sensing pathogens and initiating adaptive immune responses. Early innate signatures have been identified that can predict the immunogenicity of vaccines, highlighting the dynamic interaction between innate and adaptive immunity (Pulendran et al., 2010; Furman & Davis, 2015).

The overall efficacy of a vaccine is influenced not only by the nature of the antigens used but also by how well they are presented to the immune system. This includes factors such as the purity and stability of the antigens, the appropriate composition of the vaccine, and the use of innovative adjuvants that enhance the immune response (Zepp, 2010; Saylor et al., 2020). The careful design of vaccine antigens, considering their structure and the way they interact with immune receptors, is crucial for inducing a strong and protective immune response (Sallusto et al., 2010).

In summary, the immune system responds to vaccines through a well-coordinated process involving antigen presentation by APCs, activation of T cells via MHC molecules, and the interplay between innate and adaptive immune responses. Understanding these mechanisms is vital for the development of effective vaccines that can provide long-lasting protection against infectious diseases.

3.2 Activation of T and B Cells ​

The immune response to vaccines involves a complex interplay between various components of the immune system, primarily focusing on the activation of T and B cells, which are essential for establishing immunological memory and providing protection against pathogens.

Vaccination initiates an immune response that is characterized by the activation of both the innate and adaptive immune systems. The innate immune response serves as the first line of defense and plays a critical role in shaping the adaptive immune response. Upon vaccination, antigen-presenting cells (APCs), such as dendritic cells, capture and process the vaccine antigens. These APCs then migrate to the lymph nodes, where they present the processed antigens to naïve T cells, leading to their activation.

The activation of T cells can be categorized into several stages. CD4+ T helper cells are activated upon recognizing antigens presented by major histocompatibility complex (MHC) class II molecules on APCs. This activation is crucial for orchestrating the immune response, as CD4+ T cells secrete cytokines that facilitate the activation and proliferation of CD8+ cytotoxic T cells and B cells. The role of CD4+ T cells is particularly important in the context of vaccines that utilize live attenuated viruses or recombinant proteins, as these vaccines often rely on robust CD4+ T cell responses to enhance the activation of CD8+ T cells, which are responsible for directly killing infected cells [14].

CD8+ T cells, once activated, differentiate into cytotoxic T lymphocytes (CTLs) that can recognize and eliminate cells infected with the target pathogen. The cytotoxic activity of CD8+ T cells is mediated through mechanisms such as perforin and granzymes, which induce apoptosis in infected cells [14]. The induction of these T cell responses is critical for achieving rapid protection, especially in the context of emerging infectious diseases.

B cells also play a vital role in the immune response to vaccines. Upon activation, B cells undergo clonal expansion and differentiation into plasma cells that produce antibodies specific to the vaccine antigens. The initial antibody response is often short-lived, but some B cells differentiate into memory B cells, which can persist for long periods and provide long-term immunity. The quality of the antibody response can be influenced by several factors, including the type of vaccine and the nature of the immune stimulation [15].

The concept of "trained immunity" has emerged as a significant factor influencing the immune response to vaccines. This refers to the enhanced ability of innate immune cells, such as monocytes and macrophages, to respond to subsequent infections or vaccinations after an initial exposure. Trained immunity can lead to a more robust and rapid activation of both T and B cell responses upon re-exposure to the same or different antigens [16].

Moreover, the development of tissue-resident memory T (TRM) cells is crucial for providing localized protection at mucosal surfaces and other tissues. These TRM cells can quickly respond to reinfection at the site of entry, thus enhancing the overall efficacy of vaccination strategies [17].

In summary, the immune response to vaccines is a multifaceted process involving the activation and differentiation of T and B cells, with contributions from both innate and adaptive immunity. Understanding these mechanisms is essential for optimizing vaccine design and improving protective efficacy against infectious diseases.

4 Immunological Memory and Long-Term Protection ​

4.1 Formation of Memory Cells ​

The immune system's response to vaccines is fundamentally rooted in the generation of immunological memory, which is essential for long-term protection against pathogens. Vaccines work by eliciting a robust immune response that leads to the formation of memory T and B cells, crucial for future encounters with the same pathogen.

When a vaccine is administered, it introduces an antigen that mimics a pathogen, prompting the immune system to respond as if it were facing a real infection. This response involves several key components of the adaptive immune system, including CD4 T cells, CD8 T cells, and B cells. These cells are activated and proliferate, leading to the generation of effector cells that help clear the antigen, as well as memory cells that persist long after the initial immune response has waned[18].

The formation of memory cells is a complex process influenced by various factors, including the nature of the vaccine, the antigen's structure, and the individual's immune system characteristics. Memory B cells, for instance, are crucial for long-term antibody production. They can persist for years, enabling the immune system to mount a rapid and effective response upon re-exposure to the same antigen. The generation of memory B cells is significantly influenced by the strength of the initial antibody response following vaccination, with more immunogenic vaccines promoting stronger and more durable memory responses[19].

Moreover, the differentiation of T cells into memory T cells is also critical. These cells are essential for the secondary immune response and can remain in the body for extended periods, providing a faster and more efficient response upon re-infection. Recent studies have highlighted the importance of T cell metabolism in maintaining these memory cells, suggesting that metabolic pathways may play a role in their longevity and functionality[20].

The durability of immunological memory varies among different vaccines and can be affected by age, genetic factors, and environmental influences. For instance, the longevity of memory responses can differ based on the type of vaccine administered and the individual’s prior exposure to pathogens. This variability underscores the importance of ongoing research to optimize vaccine formulations and strategies to enhance immune memory and protective efficacy[21].

Overall, the success of vaccines hinges on their ability to induce a strong and lasting immunological memory, enabling the immune system to respond swiftly and effectively to future infections. This understanding is critical for the development of vaccines against emerging pathogens, such as SARS-CoV-2, where insights into immune memory can inform public health policies and vaccine strategies[22].

In summary, the immune response to vaccines is characterized by the activation of adaptive immune cells, the generation of memory cells, and the establishment of long-term protective immunity, which are all essential for defending against reinfection and maintaining public health.

4.2 Role of Memory in Vaccine Efficacy ​

The immune system's response to vaccines is fundamentally anchored in the generation of immunological memory, which is critical for long-term protection against infectious diseases. Vaccination works by eliciting an immune response that creates a pool of memory cells, including both B and T cells, which are essential for recognizing and responding to pathogens upon re-exposure.

Immunological memory is a defining feature of the adaptive immune system, allowing for a faster and more robust response to previously encountered antigens. Upon vaccination, the immune system is exposed to a specific antigen, leading to the activation and differentiation of naive B and T cells. This process results in the formation of long-lived memory B cells and T cells, which persist long after the initial exposure to the antigen. These memory cells are primed to mount a rapid and effective immune response if the host encounters the same pathogen in the future [23].

The strength and longevity of immune memory can be influenced by various factors, including the nature of the vaccine, the antigenic structure, and the immune signals that accompany vaccination. For instance, the quantity and quality of innate immune signals during the initial immune response play a significant role in shaping the adaptive immune memory [21]. Additionally, the type of memory induced by different vaccines may vary considerably, which can be affected by age, environmental factors, and genetic predispositions [24].

Studies have shown that the durability of antibody responses following vaccination is often linked to the structural characteristics of the antigens used. Multivalent antigens tend to elicit more prolonged immune responses compared to monovalent ones, as they can stimulate a more extensive activation of memory B cells [25]. Furthermore, the relationship between T cell help and the generation of memory B cells is crucial; T helper cells are essential for the differentiation of B cells into long-lived memory cells and plasma cells, which secrete antibodies [26].

Recent advancements in understanding the dynamics of immunological memory highlight that the immune response is not static. For example, the concept of "original antigenic sin" describes how prior exposures to certain antigens can influence the immune response to subsequent vaccinations, potentially impacting vaccine efficacy [27]. This emphasizes the importance of carefully designing vaccines to ensure they not only induce robust memory but also adapt to the evolving nature of pathogens.

In conclusion, the immune system's response to vaccines is characterized by the induction of a complex and multifaceted immunological memory. This memory enables a more effective and swift response upon re-exposure to pathogens, ultimately determining the long-term efficacy of vaccines. Understanding the mechanisms that underlie this memory formation is essential for the rational design of future vaccines that can provide durable protection against infectious diseases [28].

5 Factors Influencing Vaccine Response ​

5.1 Age and Immune Status ​

The immune response to vaccines is significantly influenced by various factors, with age and immune status being critical determinants. Immunosenescence, a term that describes the gradual deterioration of the immune system associated with aging, plays a pivotal role in shaping the vaccine responses in older adults.

As individuals age, their immune systems undergo characteristic changes that result in decreased efficacy of vaccine responses. This decline is observed in both humoral (antibody-mediated) and cellular (T cell-mediated) immunity. For instance, studies have shown that older adults exhibit significantly reduced antibody formation in response to vaccinations, such as the hepatitis B vaccine, compared to younger populations. Specifically, individuals with a mean age of 61 years demonstrated a markedly lower antibody response than those with a mean age of 33 years, indicating that aging impairs the immune response to vaccination (Rosenberg et al., 2013) [29].

Moreover, the functionality of T cells also declines with age. T cell-mediated responses, which are crucial for effective vaccination, are reshaped during aging. The reduced proliferative capacity of T cells, particularly the CD4+ and CD8+ subsets, contributes to diminished vaccine efficacy in older adults (Pereira et al., 2020) [30]. This impairment is compounded by a chronic low-level inflammatory state, referred to as "inflammaging," which has been shown to inhibit immune responses to vaccines (Bell & Kutzler, 2022) [31].

In addition to age, the overall immune status, including the presence of frailty, significantly impacts vaccine responsiveness. Frailty, characterized by a decline in physiological reserve and function, is prevalent among older adults and is associated with further acceleration of immunosenescence. Research indicates that frail individuals exhibit lower immune responses to vaccines compared to their non-frail counterparts, highlighting the importance of assessing immune status when considering vaccination strategies (Moehling et al., 2018) [32].

The aging immune system also experiences alterations in the innate immune response, which serves as the first line of defense against pathogens. Changes in neutrophil function, dendritic cell activity, and the overall diversity of the immune repertoire further complicate the vaccine response in older adults (Oh et al., 2019) [33].

In conclusion, age-related changes in both the innate and adaptive immune systems lead to a decreased ability to respond to vaccinations effectively. This underscores the need for tailored vaccination strategies that consider the unique challenges posed by immunosenescence, such as the development of new vaccine formulations and adjuvants specifically designed to enhance immunogenicity in older populations (Dorrington & Bowdish, 2013) [34]. Understanding these factors is essential for improving vaccine efficacy and ensuring better protection for older adults against infectious diseases.

5.2 Genetic Factors and Pre-existing Immunity ​

The immune response to vaccines is a complex interplay of various factors, including genetic predispositions and pre-existing immunity. A substantial body of research has identified that individual variability in vaccine responses can be attributed to both intrinsic genetic factors and extrinsic environmental influences.

Genetic factors play a significant role in determining how effectively an individual responds to vaccination. Variants in genes that encode immune response proteins, including those involved in innate and adaptive immunity, have been linked to variations in vaccine efficacy. For instance, polymorphisms in genes encoding Toll-like receptors, human leukocyte antigen (HLA) molecules, cytokines, and cytokine receptors have been associated with differing responses to a variety of vaccines, such as those for measles, hepatitis B, and influenza [35]. These genetic variations can influence both the magnitude and quality of the immune response, potentially leading to either robust or suboptimal seroconversion.

In addition to genetic factors, pre-existing immunity significantly affects vaccine responses. This includes immunity that may arise from previous infections or vaccinations. The presence of pre-existing antibodies or immune memory can enhance or modulate the immune response to a new vaccine, potentially leading to quicker and more robust protective effects [36]. Conversely, pre-existing immunity can sometimes interfere with the effectiveness of a vaccine, particularly if the vaccine targets the same pathogen as a previous exposure.

Environmental factors also contribute to the immune response. For example, the gut microbiota composition has been shown to influence vaccine efficacy, with certain microbial profiles potentially enhancing immune responses [37]. Additionally, factors such as age, sex, nutritional status, and comorbidities can further modulate how an individual’s immune system reacts to a vaccine [38].

Recent advances in systems biology and immunogenomics have allowed researchers to better understand these interactions and identify potential biomarkers that predict vaccine responsiveness [39]. For instance, the baseline immune state (BIS) of an individual, which includes their pre-vaccination immune profile, has been linked to the strength of the immune response post-vaccination [40]. This understanding may lead to personalized vaccination strategies that take into account an individual's genetic makeup and existing immune status to optimize vaccine efficacy.

In summary, the immune response to vaccines is influenced by a multitude of factors, including genetic variations that affect immune function, the presence of pre-existing immunity, and various environmental conditions. Understanding these factors is crucial for improving vaccine design and effectiveness across diverse populations.

6 Innovations in Vaccine Development ​

6.1 Novel Vaccine Platforms ​

The immune system's response to vaccines is a complex and multifaceted process that engages both innate and adaptive immunity. Recent advancements in vaccine development have introduced novel platforms that enhance this immune response through various innovative mechanisms.

Vaccines aim to elicit a robust immune response, typically characterized by the activation of both humoral (antibody-mediated) and cellular (T-cell mediated) immunity. An effective vaccine should ideally provide long-lasting protection against pathogens by engaging these immune pathways effectively. Traditional vaccine strategies often faced limitations in inducing strong cell-mediated immune responses and protective mucosal immunity. However, emerging platforms are addressing these challenges by improving antigen stability and immunogenicity.

For instance, a study highlighted the use of α-galactose modified antigens combined with amphiphilic polyanhydride nanoparticles as vaccine delivery vehicles. This innovative approach resulted in a high titer, high avidity antibody response with broader epitope recognition than traditional regimens, demonstrating enhanced proliferation of antigen-specific CD4(+) T cells compared to conventional adjuvants (Phanse et al., 2014) [41].

Another promising platform involves the use of injectable hydrogels for the sustained co-delivery of subunit vaccines. This method prolongs the exposure of the immune system to vaccine components, which significantly enhances the magnitude, duration, and quality of the humoral immune response. The hydrogel-based approach led to a more than 1000-fold increase in antigen-specific antibody affinity compared to standard administration methods, highlighting the importance of sustained antigen presentation in vaccine efficacy (Roth et al., 2020) [42].

Moreover, advancements in systems biology and immunogenomics are enabling a more rational approach to vaccine design. By analyzing immune responses at a systems level, researchers can uncover interactions between innate and adaptive immune responses, leading to the identification of effective vaccine candidates. This systems vaccinology approach integrates high-throughput data to understand the immune response better, ultimately informing the design of next-generation vaccines (Pezeshki et al., 2019) [43].

The use of nanotechnology in vaccine development has also gained traction, with nanoparticles serving as carriers for antigens and adjuvants. These materials can enhance antigen delivery and stability, thus improving the overall immune response. For example, nanomaterials have been utilized to create vaccines that target intracellular bacterial pathogens, showing promise in inducing robust immune responses and improving survival outcomes in preclinical models (Files et al., 2022) [44].

Furthermore, mRNA vaccine platforms, which gained prominence during the COVID-19 pandemic, exemplify the potential of innovative vaccine technologies. These platforms not only deliver the antigen effectively but also modulate the innate immune response, contributing to the development of adaptive immunity. Research into how mRNA nanoplatforms influence immune responses continues to evolve, with a focus on optimizing their efficacy and safety (Wei et al., 2024) [45].

In summary, the immune system responds to vaccines through a well-coordinated interplay of innate and adaptive mechanisms. Innovations in vaccine platforms, such as nanoparticle delivery systems, injectable hydrogels, and mRNA technologies, are significantly enhancing the immune response by improving antigen presentation, stability, and the overall efficacy of vaccines. These advancements are crucial for developing effective countermeasures against emerging infectious diseases and improving public health outcomes.

6.2 Role of Adjuvants and Delivery Systems ​

Vaccines play a critical role in public health by inducing immune responses that protect against infectious diseases. The immune system's response to vaccines is multifaceted, involving both the innate and adaptive immune systems. Upon vaccination, the innate immune response is triggered, which includes the activation of antigen-presenting cells (APCs) such as dendritic cells. These cells process the vaccine antigens and present them to T cells, thereby initiating an adaptive immune response tailored to the specific pathogen.

Adjuvants are essential components in many vaccines, serving to enhance, modulate, and prolong the immune response. For over 90 years, adjuvants have been utilized to improve vaccine efficacy by stimulating the innate immune system. They act by delivering a localized activation signal that promotes the development of an antigen-specific adaptive immune response [46]. Various adjuvants can enhance the magnitude, breadth, and durability of the immune response, thereby increasing the overall effectiveness of vaccines [47].

Recent advancements in vaccine development have highlighted the importance of understanding the mechanisms of action of adjuvants. Research indicates that novel adjuvants can stimulate innate immune sensors and target antigens to dendritic cells, enhancing both the quantitative and qualitative aspects of the adaptive immune response [48]. This includes the development of new adjuvant formulations and systems that are better suited to elicit the desired immune responses, particularly in the context of complex pathogens [49].

Delivery systems also play a crucial role in vaccine efficacy. These systems ensure that the antigen and adjuvant are localized to the appropriate immune compartments, thereby facilitating a more effective immune response. Innovations in delivery methods, such as nanoparticle systems and alternative routes of administration (e.g., intradermal or edible vaccines), are being explored to enhance immunogenicity and trigger robust immune responses [50][51].

Furthermore, the integration of systems biology into vaccine research has provided new insights into how vaccines interact with the immune system. This approach allows for a more detailed understanding of the biological events elicited by vaccination and the factors influencing immune responses, including sex, age, and genetic background [52]. Such knowledge is vital for the rational design of future vaccines that are tailored to produce effective immune responses against emerging infectious diseases [53].

In summary, the immune response to vaccines is a complex interplay between the innate and adaptive immune systems, significantly influenced by the use of adjuvants and delivery systems. The ongoing research in these areas is critical for developing more effective vaccines that can provide better protection against a wide range of infectious diseases.

7 Conclusion ​

The immune response to vaccines is a multifaceted process that involves the intricate interplay between the innate and adaptive immune systems. Key findings highlight that the initial response is predominantly mediated by the innate immune system, which activates various immune cells and sets the stage for the adaptive response characterized by T and B cell activation. This coordinated response not only results in the production of antibodies but also establishes immunological memory, which is crucial for long-term protection against pathogens. Current research emphasizes the variability of vaccine responses influenced by factors such as age, genetic predispositions, and pre-existing immunity, underscoring the necessity for personalized vaccination strategies. Future directions in vaccine research should focus on optimizing vaccine formulations, incorporating novel platforms and adjuvants, and leveraging insights from systems biology to enhance immunogenicity and efficacy. As the landscape of infectious diseases evolves, particularly in light of recent global health challenges, understanding these immune mechanisms will be vital for developing effective vaccines that can provide robust protection across diverse populations.

References ​

  • [1] David Furman;Mark M Davis. New approaches to understanding the immune response to vaccination and infection.. Vaccine(IF=3.5). 2015. PMID:26232539. DOI: .
  • [2] Bali Pulendran;Shuzhao Li;Helder I Nakaya. Systems vaccinology.. Immunity(IF=26.3). 2010. PMID:21029962. DOI: 10.1016/j.immuni.2010.10.006.
  • [3] Diana Lourdes Padilla-Bórquez;Mónica Guadalupe Matuz-Flores;Jorge Hernández-Bello;Jesús Alfredo Rosas-Rodríguez;Francisco Javier Turrubiates-Hernández;Samuel García-Arellano;Guillermo González-Estevez;Hazael Ramiro Ceja-Galvez;Edith Oregon-Romero;Alberto López-Reyes;Jose Francisco Muñoz-Valle. Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses.. Human vaccines & immunotherapeutics(IF=3.5). 2024. PMID:39246041. DOI: 10.1080/21645515.2024.2394265.
  • [4] Bruna T Tiyo;Gabriela J H Schmitz;Marina M Ortega;Laís T da Silva;Alexandre de Almeida;Telma M Oshiro;Alberto J da S Duarte. What Happens to the Immune System after Vaccination or Recovery from COVID-19?. Life (Basel, Switzerland)(IF=3.4). 2021. PMID:34833028. DOI: 10.3390/life11111152.
  • [5] Arun B Arunachalam. Vaccines Induce Homeostatic Immunity, Generating Several Secondary Benefits.. Vaccines(IF=3.4). 2024. PMID:38675778. DOI: 10.3390/vaccines12040396.
  • [6] H Van Loveren;J G Van Amsterdam;R J Vandebriel;T G Kimman;H C Rümke;P S Steerenberg;J G Vos. Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors.. Environmental health perspectives(IF=9.8). 2001. PMID:11564609. DOI: 10.1289/ehp.01109757.
  • [7] Jane Kasten-Jolly;David A Lawrence. Cellular and Molecular Immunity to Influenza Viruses and Vaccines.. Vaccines(IF=3.4). 2024. PMID:38675771. DOI: 10.3390/vaccines12040389.
  • [8] Petra Zimmermann;Nigel Curtis. The influence of the intestinal microbiome on vaccine responses.. Vaccine(IF=3.5). 2018. PMID:29909134. DOI: 10.1016/j.vaccine.2018.04.066.
  • [9] Alexander Winkelmann;Micha Loebermann;Michael Barnett;Hans-Peter Hartung;Uwe K Zettl. Vaccination and immunotherapies in neuroimmunological diseases.. Nature reviews. Neurology(IF=33.1). 2022. PMID:35388213. DOI: 10.1038/s41582-022-00646-5.
  • [10] Carlo Airola;Silvia Andaloro;Antonio Gasbarrini;Francesca Romana Ponziani. Vaccine Responses in Patients with Liver Cirrhosis: From the Immune System to the Gut Microbiota.. Vaccines(IF=3.4). 2024. PMID:38675732. DOI: 10.3390/vaccines12040349.
  • [11] Nathaniel D Lambert;Inna G Ovsyannikova;V Shane Pankratz;Robert M Jacobson;Gregory A Poland. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach.. Expert review of vaccines(IF=4.8). 2012. PMID:23002979. DOI: 10.1586/erv.12.61.
  • [12] Thomas Hagan;Bram Gerritsen;Lewis E Tomalin;Slim Fourati;Matthew P Mulè;Daniel G Chawla;Dmitri Rychkov;Evan Henrich;Helen E R Miller;Joann Diray-Arce;Patrick Dunn;Audrey Lee; ;Ofer Levy;Raphael Gottardo;Minne M Sarwal;John S Tsang;Mayte Suárez-Fariñas;Rafick-Pierre Sékaly;Steven H Kleinstein;Bali Pulendran. Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses.. Nature immunology(IF=27.6). 2022. PMID:36316475. DOI: 10.1038/s41590-022-01328-6.
  • [13] Kristine L Bucasas;Luis M Franco;Chad A Shaw;Molly S Bray;Janet M Wells;Diane Niño;Nancy Arden;John M Quarles;Robert B Couch;John W Belmont. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans.. The Journal of infectious diseases(IF=4.5). 2011. PMID:21357945. DOI: 10.1093/infdis/jiq156.
  • [14] Melanie Kremer;Yasemin Suezer;Asisa Volz;Theresa Frenz;Monir Majzoub;Kay-Martin Hanschmann;Michael H Lehmann;Ulrich Kalinke;Gerd Sutter. Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox.. PLoS pathogens(IF=4.9). 2012. PMID:22396645. DOI: 10.1371/journal.ppat.1002557.
  • [15] Jean-Louis Palgen;Yanis Feraoun;Gaëlle Dzangué-Tchoupou;Candie Joly;Frédéric Martinon;Roger Le Grand;Anne-Sophie Beignon. Optimize Prime/Boost Vaccine Strategies: Trained Immunity as a New Player in the Game.. Frontiers in immunology(IF=5.9). 2021. PMID:33763063. DOI: 10.3389/fimmu.2021.612747.
  • [16] C Kim;F Fang;C M Weyand;J J Goronzy. The life cycle of a T cell after vaccination - where does immune ageing strike?. Clinical and experimental immunology(IF=3.8). 2017. PMID:27324743. DOI: 10.1111/cei.12829.
  • [17] Mieszko M Wilk;Kingston H G Mills. CD4 TRM Cells Following Infection and Immunization: Implications for More Effective Vaccine Design.. Frontiers in immunology(IF=5.9). 2018. PMID:30147701. DOI: 10.3389/fimmu.2018.01860.
  • [18] Alessandro Sette;Shane Crotty. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines.. Immunological reviews(IF=8.3). 2022. PMID:35733376. DOI: 10.1111/imr.13089.
  • [19] J Banatvala;P Van Damme;S Oehen. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory.. Vaccine(IF=3.5). 2000. PMID:11115711. DOI: 10.1016/s0264-410x(00)00224-3.
  • [20] Mauro Corrado;Erika L Pearce. Targeting memory T cell metabolism to improve immunity.. The Journal of clinical investigation(IF=13.6). 2022. PMID:34981777. DOI: .
  • [21] Flora Castellino;Grazia Galli;Giuseppe Del Giudice;Rino Rappuoli. Generating memory with vaccination.. European journal of immunology(IF=3.7). 2009. PMID:19637203. DOI: 10.1002/eji.200939550.
  • [22] Isaak Quast;David Tarlinton. B cell memory: understanding COVID-19.. Immunity(IF=26.3). 2021. PMID:33513337. DOI: 10.1016/j.immuni.2021.01.014.
  • [23] Shane Crotty;Rafi Ahmed. Immunological memory in humans.. Seminars in immunology(IF=7.8). 2004. PMID:15130504. DOI: 10.1016/j.smim.2004.02.008.
  • [24] Tri Giang Phan;Stuart G Tangye. Memory B cells: total recall.. Current opinion in immunology(IF=5.8). 2017. PMID:28363157. DOI: 10.1016/j.coi.2017.03.005.
  • [25] Mark K Slifka;Ian J Amanna. Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses.. Frontiers in immunology(IF=5.9). 2019. PMID:31118935. DOI: 10.3389/fimmu.2019.00956.
  • [26] A F Ochsenbein;D D Pinschewer;S Sierro;E Horvath;H Hengartner;R M Zinkernagel. Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs.. Proceedings of the National Academy of Sciences of the United States of America(IF=9.1). 2000. PMID:11069289. DOI: 10.1073/pnas.230417497.
  • [27] Sarah Cobey. Vaccination against rapidly evolving pathogens and the entanglements of memory.. Nature immunology(IF=27.6). 2024. PMID:39384979. DOI: 10.1038/s41590-024-01970-2.
  • [28] Federica Sallusto;Antonio Lanzavecchia;Koichi Araki;Rafi Ahmed. From vaccines to memory and back.. Immunity(IF=26.3). 2010. PMID:21029957. DOI: 10.1016/j.immuni.2010.10.008.
  • [29] Carina Rosenberg;Nicolai V Bovin;Lone Valentin Bram;Eigil Flyvbjerg;Mogens Erlandsen;Thomas Vorup-Jensen;Eskild Petersen. Age is an important determinant in humoral and T cell responses to immunization with hepatitis B surface antigen.. Human vaccines & immunotherapeutics(IF=3.5). 2013. PMID:23571167. DOI: 10.4161/hv.24480.
  • [30] Branca Pereira;Xiao-Ning Xu;Arne N Akbar. Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly.. Frontiers in immunology(IF=5.9). 2020. PMID:33178213. DOI: 10.3389/fimmu.2020.583019.
  • [31] Matthew R Bell;Michele A Kutzler. An old problem with new solutions: Strategies to improve vaccine efficacy in the elderly.. Advanced drug delivery reviews(IF=17.6). 2022. PMID:35202770. DOI: 10.1016/j.addr.2022.114175.
  • [32] Krissy K Moehling;Mary Patricia Nowalk;Chyongchiou Jeng Lin;Marnie Bertolet;Ted M Ross;Chalise E Carter;Michael Susick;Sean G Saul;A Murat Kaynar;Joyce T Bromberger;Richard K Zimmerman. The effect of frailty on HAI response to influenza vaccine among community-dwelling adults ≥ 50 years of age.. Human vaccines & immunotherapeutics(IF=3.5). 2018. PMID:29172948. DOI: 10.1080/21645515.2017.1405883.
  • [33] Soo-Jin Oh;Jae Kyung Lee;Ok Sarah Shin. Aging and the Immune System: the Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity.. Immune network(IF=4.1). 2019. PMID:31921467. DOI: 10.4110/in.2019.19.e37.
  • [34] Michael G Dorrington;Dawn M E Bowdish. Immunosenescence and novel vaccination strategies for the elderly.. Frontiers in immunology(IF=5.9). 2013. PMID:23825474. DOI: 10.3389/fimmu.2013.00171.
  • [35] Melanie J Newport. The genetic regulation of infant immune responses to vaccination.. Frontiers in immunology(IF=5.9). 2015. PMID:25699041. DOI: 10.3389/fimmu.2015.00018.
  • [36] Petra Zimmermann;Nigel Curtis. Factors That Influence the Immune Response to Vaccination.. Clinical microbiology reviews(IF=19.3). 2019. PMID:30867162. DOI: 10.1128/CMR.00084-18.
  • [37] Pierluigi Rio;Mario Caldarelli;Monica Chiantore;Francesca Ocarino;Marcello Candelli;Antonio Gasbarrini;Giovanni Gambassi;Rossella Cianci. Immune Cells, Gut Microbiota, and Vaccines: A Gender Perspective.. Cells(IF=5.2). 2024. PMID:38534370. DOI: 10.3390/cells13060526.
  • [38] Juan Bautista De Sanctis;Germán Balda Noria;Alexis Hipólito García. Exploring How Adipose Tissue, Obesity, and Gender Influence the Immune Response to Vaccines: A Comprehensive Narrative Review.. International journal of molecular sciences(IF=4.9). 2025. PMID:39859575. DOI: 10.3390/ijms26020862.
  • [39] Luigi Buonaguro;Bali Pulendran. Immunogenomics and systems biology of vaccines.. Immunological reviews(IF=8.3). 2011. PMID:21198673. DOI: 10.1111/j.1600-065X.2010.00971.x.
  • [40] Djamel Nehar-Belaid;Mark Sokolowski;Sathyabaarathi Ravichandran;Jacques Banchereau;Damien Chaussabel;Duygu Ucar. Baseline immune states (BIS) associated with vaccine responsiveness and factors that shape the BIS.. Seminars in immunology(IF=7.8). 2023. PMID:37717525. DOI: 10.1016/j.smim.2023.101842.
  • [41] Yashdeep Phanse;Brenda R Carrillo-Conde;Amanda E Ramer-Tait;Scott Broderick;Chang Sun Kong;Krishna Rajan;Ramon Flick;Robert B Mandell;Balaji Narasimhan;Michael J Wannemuehler. A systems approach to designing next generation vaccines: combining α-galactose modified antigens with nanoparticle platforms.. Scientific reports(IF=3.9). 2014. PMID:24441019. DOI: 10.1038/srep03775.
  • [42] Gillie A Roth;Emily C Gale;Marcela Alcántara-Hernández;Wei Luo;Eneko Axpe;Rohit Verma;Qian Yin;Anthony C Yu;Hector Lopez Hernandez;Caitlin L Maikawa;Anton A A Smith;Mark M Davis;Bali Pulendran;Juliana Idoyaga;Eric A Appel. Injectable Hydrogels for Sustained Codelivery of Subunit Vaccines Enhance Humoral Immunity.. ACS central science(IF=10.4). 2020. PMID:33145416. DOI: 10.1021/acscentsci.0c00732.
  • [43] Abdulmohammad Pezeshki;Inna G Ovsyannikova;Brett A McKinney;Gregory A Poland;Richard B Kennedy. The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines.. Expert review of vaccines(IF=4.8). 2019. PMID:30700167. DOI: 10.1080/14760584.2019.1575208.
  • [44] Megan A Files;Kadin M Kristjansson;Jai S Rudra;Janice J Endsley. Nanomaterials-based vaccines to target intracellular bacterial pathogens.. Frontiers in microbiology(IF=4.5). 2022. PMID:36466676. DOI: 10.3389/fmicb.2022.1040105.
  • [45] Lai Wei;Chunhong Dong;Wandi Zhu;Bao-Zhong Wang. mRNA Vaccine Nanoplatforms and Innate Immunity.. Viruses(IF=3.5). 2024. PMID:38257820. DOI: 10.3390/v16010120.
  • [46] Ying Cui;Megan Ho;Yongjie Hu;Yuan Shi. Vaccine adjuvants: current status, research and development, licensing, and future opportunities.. Journal of materials chemistry. B(IF=5.7). 2024. PMID:38591323. DOI: 10.1039/d3tb02861e.
  • [47] Bali Pulendran;Prabhu S Arunachalam;Derek T O'Hagan. Emerging concepts in the science of vaccine adjuvants.. Nature reviews. Drug discovery(IF=101.8). 2021. PMID:33824489. DOI: 10.1038/s41573-021-00163-y.
  • [48] Stuart M Levitz;Douglas T Golenbock. Beyond empiricism: informing vaccine development through innate immunity research.. Cell(IF=42.5). 2012. PMID:22424235. DOI: 10.1016/j.cell.2012.02.012.
  • [49] Geert Leroux-Roels. Unmet needs in modern vaccinology: adjuvants to improve the immune response.. Vaccine(IF=3.5). 2010. PMID:20713254. DOI: 10.1016/j.vaccine.2010.07.021.
  • [50] Ru Wen;Afoma C Umeano;Yi Kou;Jian Xu;Ammad Ahmad Farooqi. Nanoparticle systems for cancer vaccine.. Nanomedicine (London, England)(IF=3.9). 2019. PMID:30806568. DOI: 10.2217/nnm-2018-0147.
  • [51] E Criscuolo;V Caputo;R A Diotti;G A Sautto;G A Kirchenbaum;N Clementi. Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines.. Journal of immunology research(IF=3.6). 2019. PMID:30949518. DOI: 10.1155/2019/8303648.
  • [52] Genada Sinani;Sevda Şenel. Advances in vaccine adjuvant development and future perspectives.. Drug delivery(IF=8.1). 2025. PMID:40536024. DOI: 10.1080/10717544.2025.2517137.
  • [53] Derek T O'Hagan;Leonard R Friedland;Emmanuel Hanon;Arnaud M Didierlaurent. Towards an evidence based approach for the development of adjuvanted vaccines.. Current opinion in immunology(IF=5.8). 2017. PMID:28755542. DOI: 10.1016/j.coi.2017.07.010.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Immune System · Vaccines · Immune Response · Immunological Memory · Personalized Vaccination Strategies

© 2025 MaltSci